Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2018

03.11.2017 | Original Article

A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

verfasst von: Vincent A. de Weger, Sanjay Goel, Roger von Moos, Jan H. M. Schellens, Nicholas Mach, Eugene Tan, Suraj Anand, Jeffrey W. Scott, Ulrik Lassen

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1–3, FGFR 1–3, and PDGFR. This study was performed to investigate the potential drug–drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors.

Methods

Non-smoking patients of ≥ 18 years with advanced solid tumors, excluding breast cancer, were included. Patients were treated with a dose of 300 mg in 5 days on/2 days off schedule. Steady-state pharmacokinetic assessments of dovitinib were performed with or without fluvoxamine.

Results

Forty-five patients were enrolled; 24 were evaluable for drug–drug interaction assessment. Median age was 60 years (range 30–85). At steady state the geometric mean for dovitinib (coefficient of variation%) of the area under the plasma concentration–time curve (AUC0–72h) and maximum concentration (C max) were 2880 ng/mL h (47%) and 144 ng/mL (41%), respectively. Following administration of dovitinib in combination with fluvoxamine the geometric mean of dovitinib AUC0–72h and C max were 8290 ng/mL h (60%) and 259 ng/mL (45%), respectively. The estimated geometric mean ratios for dovitinib AUC0–72h and C max (dovitinib + fluvoxamine vs. dovitinib alone) were 2.88 [90% confidence interval (CI) 2.58, 3.20] and 1.80 (90% CI 1.66, 1.95). This effect is considered a moderate drug–drug interaction.

Conclusions

Fluvoxamine co-administration resulted in a 80% increase in C max and a 188% increase in AUC0–72h of dovitinib. Given the increase in exposure to dovitinib observed, patients are at risk of dovitinib related toxicity. Dovitinib should, therefore, not be co-administered with moderate and strong CYP1A2 inhibitors, without dose reduction.
Literatur
1.
Zurück zum Zitat Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, Lapointe GR, Feucht PH, Warne RL, Heise CC, Menezes D, Aardalen K, Ye H, He M, Le V, Vora J, Jansen JM, Wernette-Hammond ME, Harris AL (2009) Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 52:278–292. doi:10.1021/jm800790t CrossRefPubMed Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, Lapointe GR, Feucht PH, Warne RL, Heise CC, Menezes D, Aardalen K, Ye H, He M, Le V, Vora J, Jansen JM, Wernette-Hammond ME, Harris AL (2009) Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 52:278–292. doi:10.​1021/​jm800790t CrossRefPubMed
2.
Zurück zum Zitat Angevin E, Lopez-Martin J a, Lin C-C, Gschwend JE, Harzstark A, Castellano D, Soria J-C, Sen P, Chang J, Shi M, Kay A, Escudier B (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:1257–1268. doi:10.1158/1078-0432.CCR-12-2885 CrossRefPubMed Angevin E, Lopez-Martin J a, Lin C-C, Gschwend JE, Harzstark A, Castellano D, Soria J-C, Sen P, Chang J, Shi M, Kay A, Escudier B (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:1257–1268. doi:10.​1158/​1078-0432.​CCR-12-2885 CrossRefPubMed
3.
Zurück zum Zitat Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451–7461. doi:10.1158/1078-0432.CCR-11-1747 CrossRefPubMed Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451–7461. doi:10.​1158/​1078-0432.​CCR-11-1747 CrossRefPubMed
4.
Zurück zum Zitat Sarker D, Molife R, Evans TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14:2075–2081. doi:10.1158/1078-0432.CCR-07-1466 CrossRefPubMed Sarker D, Molife R, Evans TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14:2075–2081. doi:10.​1158/​1078-0432.​CCR-07-1466 CrossRefPubMed
5.
Zurück zum Zitat Escudier B, Grünwald V, Ravaud A, Ou Y-C, Castellano D, Lin C-C, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E (2014) Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res 20:3012–3022. doi:10.1158/1078-0432.CCR-13-3006 CrossRefPubMed Escudier B, Grünwald V, Ravaud A, Ou Y-C, Castellano D, Lin C-C, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E (2014) Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res 20:3012–3022. doi:10.​1158/​1078-0432.​CCR-13-3006 CrossRefPubMed
6.
Zurück zum Zitat Kang Y-K, Yoo C, Ryoo B-Y, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu J-S, Ryu M-H (2013) Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer 109:2309–2315. doi:10.1038/bjc.2013.594 CrossRefPubMedPubMedCentral Kang Y-K, Yoo C, Ryoo B-Y, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu J-S, Ryu M-H (2013) Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer 109:2309–2315. doi:10.​1038/​bjc.​2013.​594 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Keam B, Kim S-B, Shin SH, Cho BC, Lee K-W, Kim MK, Yun H-J, Lee S-H, Yoon DH, Bang Y-J (2015) Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 121:2612–2617. doi:10.1002/cncr.29401 CrossRefPubMed Keam B, Kim S-B, Shin SH, Cho BC, Lee K-W, Kim MK, Yun H-J, Lee S-H, Yoon DH, Bang Y-J (2015) Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 121:2612–2617. doi:10.​1002/​cncr.​29401 CrossRefPubMed
8.
Zurück zum Zitat Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R (2015) Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 16:686–694. doi:10.1016/S1470-2045(15)70159-2 CrossRefPubMed Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R (2015) Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 16:686–694. doi:10.​1016/​S1470-2045(15)70159-2 CrossRefPubMed
9.
Zurück zum Zitat Lim SM, Chung WY, Nam K-H, Kang S-W, Lim JY, Kim H-G, Shin SH, Sun J-M, Kim S-G, Kim J-H, Kang CW, Kim HR, Cho BC (2015) An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer 51:1588–1595. doi:10.1016/j.ejca.2015.05.020 CrossRefPubMed Lim SM, Chung WY, Nam K-H, Kang S-W, Lim JY, Kim H-G, Shin SH, Sun J-M, Kim S-G, Kim J-H, Kang CW, Kim HR, Cho BC (2015) An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer 51:1588–1595. doi:10.​1016/​j.​ejca.​2015.​05.​020 CrossRefPubMed
10.
Zurück zum Zitat Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN (2014) Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer 50:3145–3152. doi:10.1016/j.ejca.2014.10.013 CrossRefPubMed Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN (2014) Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer 50:3145–3152. doi:10.​1016/​j.​ejca.​2014.​10.​013 CrossRefPubMed
11.
Zurück zum Zitat Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol 95:316–324. doi:10.1111/ejh.12491 CrossRefPubMed Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol 95:316–324. doi:10.​1111/​ejh.​12491 CrossRefPubMed
13.
Zurück zum Zitat Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee J-L, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15:286–296. doi:10.1016/S1470-2045(14)70030-0 CrossRefPubMedPubMedCentral Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee J-L, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15:286–296. doi:10.​1016/​S1470-2045(14)70030-0 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cheng A-L, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang T-S, Wu C-C, Chao Y, Chan SL, Kudo M, Ikeda M, Kang Y-K, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez A-M, Zhang Y, Wang Y, Poon RTP (2016) Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 64:774–784. doi:10.1002/hep.28600 CrossRefPubMed Cheng A-L, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang T-S, Wu C-C, Chao Y, Chan SL, Kudo M, Ikeda M, Kang Y-K, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez A-M, Zhang Y, Wang Y, Poon RTP (2016) Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 64:774–784. doi:10.​1002/​hep.​28600 CrossRefPubMed
15.
Zurück zum Zitat San Carlos CNPD 2013 Dovitinib [investigator brochure] San Carlos CNPD 2013 Dovitinib [investigator brochure]
16.
Zurück zum Zitat Dubbelman A-C, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JHM (2012) Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother Pharmacol 70:653–663. doi:10.1007/s00280-012-1947-2 CrossRefPubMed Dubbelman A-C, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JHM (2012) Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother Pharmacol 70:653–663. doi:10.​1007/​s00280-012-1947-2 CrossRefPubMed
17.
Zurück zum Zitat Pastrakuljic A, Tang BK, Roberts EA, Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53:531–538CrossRefPubMed Pastrakuljic A, Tang BK, Roberts EA, Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53:531–538CrossRefPubMed
19.
Zurück zum Zitat Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73–78CrossRefPubMed Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73–78CrossRefPubMed
20.
Zurück zum Zitat Rasmussen BB, Maënpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151–159CrossRefPubMedPubMedCentral Rasmussen BB, Maënpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151–159CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rasmussen BB, Nielsen TL, Brøsen K (1998) Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 83:240–245CrossRefPubMed Rasmussen BB, Nielsen TL, Brøsen K (1998) Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 83:240–245CrossRefPubMed
22.
Zurück zum Zitat Lam YWF, Alfaro CL, Ereshefsky L, Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274–1282. doi:10.1177/0091270003259216 CrossRefPubMed Lam YWF, Alfaro CL, Ereshefsky L, Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274–1282. doi:10.​1177/​0091270003259216​ CrossRefPubMed
23.
Zurück zum Zitat Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin Pharmacol 54:761–766 Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin Pharmacol 54:761–766
25.
Zurück zum Zitat Vezmar S, Miljkovic B, Vucicevic K, Timotijevic I, Prostran M, Todorovic Z, Pokrajac M (2009) Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 110:98–104CrossRefPubMed Vezmar S, Miljkovic B, Vucicevic K, Timotijevic I, Prostran M, Todorovic Z, Pokrajac M (2009) Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 110:98–104CrossRefPubMed
26.
Zurück zum Zitat Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl M-L, Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141–152. doi:10.1067/mcp.2002.121788 CrossRefPubMed Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl M-L, Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141–152. doi:10.​1067/​mcp.​2002.​121788 CrossRefPubMed
Metadaten
Titel
A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
verfasst von
Vincent A. de Weger
Sanjay Goel
Roger von Moos
Jan H. M. Schellens
Nicholas Mach
Eugene Tan
Suraj Anand
Jeffrey W. Scott
Ulrik Lassen
Publikationsdatum
03.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3469-4

Weitere Artikel der Ausgabe 1/2018

Cancer Chemotherapy and Pharmacology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.